Vendredi 19 juin 2009 à 11 h 00

À l’invitation de Claudine Kieda

One consequence of diabetes mellitus is the disruption of the normal process of wound
healing. Different approaches have been tested, demonstrating the feasibility of gene
therapy for augmenting angiogenesis and consequently stimulating skin regeneration.
However, there is still a need for a more effective therapy. Both new genes and new
delivery tools have to be tested. In this seminar the significance of combined AAV-
driven gene therapy will be discussed, and the data demonstrating the effectiveness of
delivery of bicistronic vectors harboring two different growth factors will be provided.
Additionally, the result of adenoviral transfer of heme oxygenase-1, a potent anti-
inflammatory and angiogenic gene will be discussed. In sum, impaired wound healing
in diabetic mice can be improved by combined gene therapy with two angiogenic
mediators or by transfer of HO-1 gene.